[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351520-105":59,"doc-detail-351520-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","detection-of-msi-signals-from-peripheral-blood-for-monitoring-response-to-immune-checkpoint-blockade-therapy-in-patients-with-advanced-microsatellite-unstable-gastrointestinal-cancers-a-pilot-study","Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite-unstable gastrointestinal cancers: A pilot study","","Microsatellite instability (MSI) is linked to strong tumor immunogenicity via neoantigen abundance, yet many patients with MSI gastrointestinal cancers do not benefit from immune checkpoint blockade (ICB). This pilot study evaluates whether MSI detection in extracellular vesicle (EV) DNA from peripheral blood can monitor ICB response and compares it with cell-free (cf) DNA. Blood (n=52) and tumor tissue (n=16) from 19 patients were analyzed using four mononucleotide markers, including plasma from 18 patients and 30 controls.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/detection-of-msi-signals-from-peripheral-blood-for-monitoring-response-to-immune-checkpoint-blockade-therapy-in-patients-with-advanced-microsatellite-unstable-gastrointestinal-cancers-a-pilot-study/351520/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/detection-of-msi-signals-from-peripheral-blood-for-monitoring-response-to-immune-checkpoint-blockade-therapy-in-patients-with-advanced-microsatellite-unstable-gastrointestinal-cancers-a-pilot-study/351520.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarker approach does this study assess for monitoring ICB therapy response?","Question",{"text":112,"@type":113},"The study evaluates MSI detection using extracellular vesicle (EV) DNA from plasma and compares it with MSI detection using cell-free (cf) DNA, both using four mononucleotide markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were samples collected and who was included in the analysis?",{"text":117,"@type":113},"Blood and tumor samples were collected from 19 patients before and during therapy, and plasma from 18 patients plus 30 healthy controls was analyzed for MSI signals.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the key performance comparison between EV DNA and cfDNA?",{"text":121,"@type":113},"MSI detection showed high concordance between EV DNA and cfDNA, reported as 93%, and healthy controls did not show MSI signals.",{"name":123,"@type":110,"acceptedAnswer":124},"Why is the EV DNA MSI transition clinically relevant?",{"text":125,"@type":113},"A shift from MSI to non-MSI status during treatment was associated with clinical benefit and objective response, often occurring before the first 3-month staging, supporting EV DNA as an early monitoring indicator.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},351520,1790147372,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","DOI: 10.1002/ijc.70387  \nRES EARCH A RTICLE  \nTumo r Markers a nd Signatures  \nDetection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite-unstable gastrointestinal cancers: A pilot study  \nAysel Ahadova 1  | Lena Bohaumilitzky 1 | Thomas Walle 2 | Joscha A. Kraske 2 | Mirjam Tariverdian 2 | Ulrike Ganserer-Schmitt 3 | Ingrid Hausser-Siller 3 |  \nVera Fuchs 1 | Nina Nelius 1 | Gizem Mehtap Erisen 1 | Johannes Gebert 1 | Albrecht Stenzinger 4,5  | Dirk Jäger 2,6 | Magnus von Knebel Doeberitz 1 | Georg Martin Haag 2,6  | Elena Busch 7 | Matthias Kloor 1  \n1Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany  \n2National Center for Tumor Diseases Heidelberg, Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany 3EMLaboratory, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany  \n4Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany  \n5German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 6Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany 7Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany  \nCorrespondence  \nAysel Ahadova and Matthias Kloor, Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.  \nEmail: aysel.ahadova@med. uni-heidelberg. de and matthias. kloor@med. uni-heidelberg.de  \nFunding information  \nElse Kröner-Fresenius-Stiftung, Grant/Award Number: 2018 _A44; Deutsche Krebshilfe, Grant/Award Number: 70113455; Klaus Tschira Stiftung, Grant/Award Number:  \n00.012.2021; Donations against Cancer, NCT Heidelberg; Stiftung für Krebs-und Scharlachforschung  \nAbstract  \nMicrosatellite instability (MSI) is associated with high immunogenicity in tumors due to the abundance of neoantigens, making MSI cancers particularly responsive to immune checkpoint blockade (ICB) therapy. However, a substantial proportion of patients with MSI gastrointestinal (GI) adenocarcinomas do not benefit from ICB, and non-invasive biomarkers for monitoring treatment response are lacking. This study investigated the utility of MSI detection in extracellular vesicle (EV) DNA as a liquid biopsy-based approach for therapy monitoring in patients with advanced MSI GI cancers undergoing ICB therapy and compared it with the analysis of cell-free (cf) DNA. Blood (n = 52) and tumor samples (n = 16) were collected from 19 patients before and during therapy. Plasma from 18 patients and 30 healthy controls was analyzed for MSI using four diagnostic mononucleotide markers in both EV DNA and cell-free DNA (cfDNA). MSI was detected in EV  \nAbbreviations: cfDNA, cell-free DNA; CR, complete response; CRC, colorectal cancer; EVs, extracellular vesicles; GI, gastrointestinal; ICB, immune checkpoint blockade; MMR, mismatch repair; MSI, microsatellite instability; NTA, nanoparticle tracking analysis; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TEM, transmission electron microscopy.  \nAysel Ahadova, Lena Bohaumilitzky, Elena Busch, and Matthias Kloor contributed equally to this work.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \n[Correction added on 07 March 2026, after first online publication: The Funding Information has been updated.] .  \nDNA in 8 out of 18 patients and in cfDNA in 9 out of 18 patients, with high concordance (93%) between the two approaches. None of the healthy controls showed MSI","cbCaisYDN3Ira1RE","https://ap.wps.com/l/cbCaisYDN3Ira1RE","pdf",4353265,12,"English","# Abstract\n# Introduction\n## DNA mismatch repair deficiency and MSI\n# Methods and study design\n## MSI detection in EV DNA vs cfDNA\n# Findings\n## Concordance and healthy control results\n## Timing of MSI-to-non-MSI transition and clinical benefit\n# Conclusion\n## EV DNA as a minimally invasive monitoring tool","[{\"question\":\"What biomarker approach does this study assess for monitoring ICB therapy response?\",\"answer\":\"The study evaluates MSI detection using extracellular vesicle (EV) DNA from plasma and compares it with MSI detection using cell-free (cf) DNA, both using four mononucleotide markers.\"},{\"question\":\"How were samples collected and who was included in the analysis?\",\"answer\":\"Blood and tumor samples were collected from 19 patients before and during therapy, and plasma from 18 patients plus 30 healthy controls was analyzed for MSI signals.\"},{\"question\":\"What was the key performance comparison between EV DNA and cfDNA?\",\"answer\":\"MSI detection showed high concordance between EV DNA and cfDNA, reported as 93%, and healthy controls did not show MSI signals.\"},{\"question\":\"Why is the EV DNA MSI transition clinically relevant?\",\"answer\":\"A shift from MSI to non-MSI status during treatment was associated with clinical benefit and objective response, often occurring before the first 3-month staging, supporting EV DNA as an early monitoring indicator.\"}]","Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite-unstable gastrointestinal cancers: A pilot study | PDF",1790094541,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87cfbf3ec998fb544e875354143fddc3.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29e5b748165806e87bc55a427265a826.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7de30baa7567829add52b7262ce3ff7.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a6f5eaf9c6ee713da170736ac826f28.webp",980,1287]